HC Wainwright & Co. Assumes MiNK Therapeutics at Buy, Announces Price Target of $38

Benzinga · 5d ago
HC Wainwright & Co. analyst Matthew Keller assumes MiNK Therapeutics (NASDAQ:INKT) with a Buy rating and announces Price Target of $38.